Actively Recruiting
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Led by New York Medical College · Updated on 2025-06-13
80
Participants Needed
3
Research Sites
334 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
CONDITIONS
Official Title
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed patients with histologically or cytologically confirmed mature B-cell non-Hodgkin lymphoma or classical Hodgkin lymphoma according to WHO Classification
- For MB-NHL: Burkitt lymphoma, Burkitt-like lymphoma with 11q aberration, diffuse large B-cell lymphoma NOS, or high grade B-cell lymphoma
- For MB-NHL Cohort Ia: stage III with LDH ≥ 2 times upper limit normal or stage IV with 5-24% bone marrow lymphoma infiltration
- For MB-NHL Cohort Ib: any CNS involvement and/or bone marrow involvement with ≥ 25% lymphoma cells or less than 20% tumor size reduction after DOC chemotherapy
- For cHL Cohort IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (intermediate risk)
- For cHL Cohort IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (high risk)
- Adequate organ function
You will not qualify if you...
- Primary mediastinal B-cell lymphoma
- T-cell/histiocyte-rich large B-cell lymphoma
- Gray zone lymphoma
- Follicular lymphoma
- Nodular lymphocyte-predominant Hodgkin lymphoma
- Posttransplant lymphoproliferative lymphoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Alabama
Birmingham, Alabama, United States, 35233
Not Yet Recruiting
2
University of Flordia
Gainsville, Florida, United States, 32610
Actively Recruiting
3
New York Medical College
Vallhala, New York, United States, 10595
Actively Recruiting
Research Team
M
Mitchell Cairo, MD
CONTACT
L
Lauren Harrison, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here